Which inhaled treatment for which patient in asthma?
This infographic describes data from the CAPTAIN study, informing on which inhaled treatment is suitable for which patients with asthma…
CHEST 2022: Real-world impact of triple therapy on asthma control in US patients
The CHEST 2022 Annual Meeting took place 16–19 October 2022 in Nashville, Tennessee, United States. The meeting provided the first in-person opportunity for attendees since 2019, showcasing over 300 educational sessions relevant for the respiratory and pulmonary fields.
Bogart M, et al. presented a poster titled ‘Real-World Impact of Triple Therapy With Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control Among Patients With Asthma in the US’ during the ‘Other topics in asthma abstract posters’ session. This analysis showed that SITT significantly reduced the use of oral corticosteroids in these patients, indicating better asthma control.
Please use the link below to view the presented poster.
View this poster in detail
Related materials
Asthma Forward is a registered trade mark of the GSK group of companies.
©2023 GSK group of companies. All rights reserved.
NX-GBL-FVU-WCNT-230002 | March 2023